Nexstim Plc to Present Depression Led Strategy at Investor Conference Sijoittaja 2018 in Helsinki

Press release, Helsinki, 19^th September 2018 at 4:00 PM EEST

Nexstim Plc to Present Depression Led Strategy at Investor Conference
Sijoittaja 2018 in Helsinki

Nexstim Plc to host a Conference Call / Webcast on Tuesday 25^th September at 4pm EEST
to Provide Strategic Update

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or the "Company"), the targeted neuromodulation company developing and marketing navigated personalised, non-invasive brain stimulation systems for the treatment of Major Depressive Disorder (MDD), announces that the Company will present its new corporate strategy and meet with investors at Sijoittaja 2018 in Helsinki, tomorrow Thursday September 20^th.

Mikko Karvinen, Chief Financial Officer, will present on the Company and its NBT System for the treatment of MDD at 12:55 at Messukeskus Helsinki, Expo and Convention Centre.

Nexstim's NBT system was approved by the FDA in November 2017 for the treatment of MDD, a recurrent and frequent chronic disorder with significant unmet clinical need. Approximately 6 million patients in the US and Europe could potentially be treated with Nextim's NBT system which  represents an estimated total treatment value of over EUR 40 billion.

The Nexstim system was successfully launched in the US at the Clinical TMS (transcranial magnetic stimulation) Society Annual Meeting, which was held in New York in May 2018. Nexstim is currently building its own direct sales force to ensure that it can maximise the potential of its highly differentiated, personalised, reimbursed NBT system.

Nexstim's NBT system provides personalised non-invasive neuro-stimulation therapy as an alternative to sub-optimal pharmacologic treatments via its SmartFocus(TM) TMS technology. TMS is used to stimulate and increase the activity of an area of the brain called the left dorsolateral prefrontal cortex (DLPFC), where metabolic activity is reduced in depression.

Nexstim NBT System is highly differentiated from other currently available TMS products. This is due to its unique and highly sophisticated 3D navigation that uses its proprietary E-field algorithm to  visualize the exact location, orientation and magnitude of the stimulation to the DLPFC 100% of the time. Other TMS systems, which do not have sophisticated 3D navigation, are believed to accurately target the precise part of the DLPFC that needs to be stimulated in only 30% of patients.